Sivers Semiconductors: Dilution Overhang Overshadows a Pivotal Strategic Pivot

Sivers Semiconductors shares fall 11% to EUR 2.16, 42% below 50-day MA, as dilution from share issues weighs despite strong order pipeline.

The market's verdict on Sivers Semiconductors is becoming increasingly difficult to ignore. Following a bruising session on Tuesday that saw the Stockholm-listed chipmaker shed another 11 percent to close at EUR 2.16, the equity now sits a staggering 42 percent below its 50-day moving average of EUR 3.70. The slide has been relentless, yet no single catalyst triggered Tuesday's drop — instead, investors appear to be digesting a confluence of structural shifts that fundamentally alter the company's equity story.

At the heart of the sell-off lies a dramatic expansion in the share count. The company confirmed that total outstanding ordinary shares stood at 356,740,332 as of August 31, swollen by a directed share issue worth approximately SEK 825 million and the full exercise of warrants by lender Bootstrap Europe IV SCSp, which subscribed for 1,659,015 new ordinary shares. That warrant exercise converted a USD 12 million convertible loan into equity, while the broader capital raise forms part of the financing package tied to the second-quarter interim report unveiled last Sunday.

The dilution is not merely theoretical — it carries real, if non-cash, consequences. The interim figures were weighed down by a SEK 42.9 million payroll tax provision triggered by the earlier surge in the share price, a quirk that exacerbated an already deteriorating bottom line. Net revenue for the quarter fell 12 percent year-on-year to SEK 53.8 million, down from SEK 61.4 million, with the currency-adjusted decline coming in at 10 percent. The first-half picture is starker still: revenue of SEK 115.6 million represents a 20 percent contraction from the SEK 144.3 million posted in the corresponding period last year, while adjusted EBITDA swung from minus SEK 20.9 million to minus SEK 35.5 million.

Management, however, frames these numbers as the cost of deliberate reinvention. Resources are being redirected away from development contracts toward scalable product revenue, a shift designed to prime the business for series production. The strategy is already showing early signs of traction: product revenue climbed 18 percent year-on-year, and the order pipeline has swelled to USD 1.2 billion as of July — a 268 percent jump since December. The company has also identified a fresh USD 4 billion addressable market for optical amplifiers in AI data centers, adding further weight to its long-term thesis.

That thesis is buttressed by a flurry of recent partnerships. A collaboration with Jabil targets an energy-efficient 1.6T pluggable optical transceiver module, while a strategic tie-up with GlobalFoundries advances silicon photonics capabilities. An USD 8.2 million production order from ALL.SPACE for Ka-band beamforming chips adds near-term commercial validation. Management anticipates a revenue inflection in the fourth quarter of 2026 as production ramps gather pace, with 2027 earmarked as the "transformational year."

The company is also exploring a secondary listing on the Nasdaq in New York — a move that could broaden its investor base and raise international visibility, though it introduces near-term uncertainty around the future share structure.

For now, the market remains unconvinced. The tension between a swelling order book and the mechanics of financing that growth through equity issuance has created a familiar dilemma: shareholders are being asked to accept near-term pain for long-term promise. Whether that patience is rewarded will depend on how swiftly the announced collaborations translate into tangible revenue. Until then, the dilution overhang is likely to remain the dominant force shaping the stock's trajectory.